Dimerix Limited (ASX: DXB) has officially received its first upfront payment of ¥300 million (~AU$3.2 million) from FUSO Pharmaceutical Industries as part of their exclusive licensing agreement for DMX-200 in Japan. This milestone brings the company one step closer to commercializing its Phase 3 kidney disease treatment for Focal Segmental Glomerulosclerosis (FSGS) in the Japanese market.
What’s Next?
- More Milestone Payments Ahead: Dimerix expects an additional ¥400 million (~AU$4.1 million) when the first clinical site in Japan is activated, which is anticipated within the next 6-12 weeks.
- Further Development & Sales Milestones: The company could earn up to ¥3.4 billion (~AU$30.6 million) in development milestones and up to ¥6.8 billion (~AU$69.4 million) in potential sales milestones.
- Royalties on Sales: If successfully commercialized, Dimerix will also receive 15-20% royalties on DMX-200 net sales in Japan.
A Growing Global Presence
FUSO is the third licensing partner for DMX-200, following agreements with Advanz Pharma (Europe) and Taiba (Middle East). Combined, these deals could bring up to AU$458 million in milestone payments and provide strong financial backing for the continued development of DMX-200.
Dimerix retains all rights to DMX-200 outside these licensed territories and is actively seeking partners in major markets like the U.S. and China.
About the Phase 3 ACTION3 Study
DMX-200 is currently being evaluated in the Phase 3 ACTION3 trial, a global, multi-center study aimed at treating FSGS, a rare and serious kidney disease. The study’s interim analyses will track proteinuria reduction and kidney function (eGFR slope), which could support marketing approval if successful.
With its third major licensing deal secured, a strong financial position, and an active global Phase 3 trial, Dimerix is making solid progress toward bringing DMX-200 to market as a potentially life-changing treatment for FSGS patients.
